Detalhe da pesquisa
1.
Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
J Allergy Clin Immunol
; 153(4): 1155-1161.e4, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38272373
2.
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy.
Clin Exp Allergy
; 54(4): 241-252, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38332535
3.
Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial).
Br J Dermatol
; 190(3): 342-354, 2024 Feb 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37936331
4.
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
J Am Acad Dermatol
; 2024 Apr 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38653344
5.
Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents.
Dermatology
; 240(2): 216-225, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38228125
6.
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Acta Derm Venereol
; 104: adv19454, 2024 02 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38323500
7.
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
Allergy
; 78(8): 2266-2276, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36934403
8.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Br J Dermatol
; 189(3): 327-335, 2023 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-37177895
9.
Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis.
Acta Derm Venereol
; 103: adv00881, 2023 Mar 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36883875
10.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Acta Derm Venereol
; 103: adv00872, 2023 Feb 16.
Artigo
Inglês
| MEDLINE | ID: mdl-36794894
11.
Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockers.
Acta Derm Venereol
; 103: adv5286, 2023 Aug 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37649330
12.
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Eur J Pediatr
; 182(2): 757-767, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36478294
13.
Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters.
J Allergy Clin Immunol
; 149(1): 125-134, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34237306
14.
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Allergy
; 77(11): 3398-3407, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35837880
15.
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Pediatr Allergy Immunol
; 33(12): e13887, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36564878
16.
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
Acta Derm Venereol
; 102: adv00666, 2022 Mar 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35098318
17.
Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma.
Acta Derm Venereol
; 102: adv00788, 2022 Oct 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35506358
18.
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Acta Derm Venereol
; 102: adv00820, 2022 Nov 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36420885
19.
Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.
Pediatr Allergy Immunol
; 32(4): 720-726, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33305439
20.
Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation.
Clin Exp Allergy
; 54(4): 294-296, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38158774